Chen Junqiang, Wu Sangang, Zheng Xiongwei, Pan Jianji, Zhu Kunshou, Chen Yuanmei, Li Jiancheng, Liao Lianming, Lin Yu, Liao Zhongxing
Department of Radiation Oncology, The Teaching Hospital of Fujian Medical University, Fujian Provincial Cancer Hospital, 91 Maluding, Fuma Road, Fuzhou, Fujian 350014, China.
BMC Surg. 2014 Dec 19;14:110. doi: 10.1186/1471-2482-14-110.
Lymph node metastasis (LNM) is most common in esophageal squamous cell carcinoma (SCC). The bi-directional spread is a key feature of LNM in patients with thoracic esophageal SCC (TE-SCC). The purpose of this study was to analyze the prognostic factors of survival in patients with TE-SCC with cervical lymph node metastasis (CLM) and validate the staging system of the current American Joint Committee on Cancer (AJCC) in a cohort of Chinese patients.
Of 1715 patients with TE-SCC who underwent radical esophagectomy plus three-field lymph node dissection at a single hospital between January 1993 and March 2007, 547 patients who had pathologically confirmed CLM (296 had surgery only and 251 had surgery + postoperative radiotherapy) were included in this study. The locations of the lymph nodes (LNs) were classified based on the guidelines of the Japanese Society for Esophageal Diseases.
The rate of CLM was 31.9% for all patients and was 44.2%, 31.5%, and 14.4% for patients with upper, middle, and lower TE-SCC, respectively (P < 0.0001). The rates of metastasis to 101 (paraesophageal lymph nodes), 104 (supraclavicular lymph nodes), 102 (deep cervical lymph nodes) and 103 (retropharyngeal lymph nodes) areas were 89.0%, 25.6%, 3.7% and 0.5%, respectively. The 5-year overall survival (OS) rate with CLM was 27.7% (median survival, 27.5 months). The 5-year OS rates were 21.3% versus 34.2% (median survival, 21.9 months versus 35.4 months) for after surgery only versus surgery + postoperative radiotherapy, respectively (P < 0.0001 for both). Multivariate analysis showed that the independent prognostic factors for survival were sex, pT stage, pN stage, number of fields with positive LNs, and treatment modality. In surgery only group, the 5-year OS rates were 24.1%, 16.2% and 11.7%, respectively, when there was metastasis to 101 LN alone, 104 LN alone or both 101 LN and 104 LN. The 5-year OS rates were 17.7%, 22.5% and 31.7%, for patients with upper, middle and lower TE-SCC , respectively (P = 0.112). The 5-year OS rates were 43.0%, 25.5%, 10.2% in patients with 1 field (cervical LNs), 2 fields (cervical + mediastinal, and/or cervical + abdominal LNs), and 3 fields (cervical + mediastinal + abdominal LNs) positive LNs, respectively (P < 0.0001). The number of fields of positive LNs did not impact the OS according to different pN stage (all P > 0.05).
Patients with TE-SCC with CLM have better prognosis, which supports the current AJCC staging system for esophageal SCC.
淋巴结转移(LNM)在食管鳞状细胞癌(SCC)中最为常见。双向扩散是胸段食管鳞状细胞癌(TE-SCC)患者LNM的一个关键特征。本研究的目的是分析伴有颈部淋巴结转移(CLM)的TE-SCC患者的生存预后因素,并在中国患者队列中验证当前美国癌症联合委员会(AJCC)的分期系统。
1993年1月至2007年3月期间,在一家医院接受根治性食管切除术加三野淋巴结清扫术的1715例TE-SCC患者中,547例经病理证实有CLM的患者(296例仅接受手术,251例接受手术+术后放疗)纳入本研究。根据日本食管疾病学会的指南对淋巴结(LNs)的位置进行分类。
所有患者的CLM发生率为31.9%,上、中、下段TE-SCC患者的CLM发生率分别为44.2%、31.5%和14.4%(P<0.0001)。转移至101区(食管旁淋巴结)、104区(锁骨上淋巴结)、102区(颈深淋巴结)和103区(咽后淋巴结)的发生率分别为89.0%、25.6%、3.7%和0.5%。伴有CLM的患者5年总生存率(OS)为27.7%(中位生存期,27.5个月)。仅手术组与手术+术后放疗组的5年OS率分别为21.3%和34.2%(中位生存期分别为21.9个月和35.4个月)(两者P<0.0001)。多因素分析显示,生存的独立预后因素为性别、pT分期、pN分期、阳性LNs的野数和治疗方式。在仅手术组中,单独转移至101区LNs、单独转移至104区LNs或同时转移至101区LNs和104区LNs时,5年OS率分别为24.1%、16.2%和11.7%。上、中、下段TE-SCC患者的5年OS率分别为17.7%、22.5%和31.7%(P=0.112)。1个野(颈部LNs)、2个野(颈部+纵隔,和/或颈部+腹部LNs)和3个野(颈部+纵隔+腹部LNs)阳性LNs的患者5年OS率分别为43.0%、25.5%、10.2%(P<0.0001)。根据不同的pN分期,阳性LNs的野数对OS无影响(所有P>0.05)。
伴有CLM的TE-SCC患者预后较好,这支持了当前AJCC食管SCC分期系统。